People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cellics Therapeutics, Inc. | — | Biotechnology | Series A | $33.0M | $116.6M | 2022 |
| Cello Therapeutics, Inc. | — | Pharma | Series A | $8.7M | $85.1M | 2022 |
Liangfang Zhang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Liangfang Zhang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jie Zhang | 2 | 3 |
| Lili Xie | 2 | 2 |
| Huiqing Zhu | 2 | 2 |
| Wei Shen | 2 | 2 |
| Weiwei Gao | 1 | 1 |
| Cihui Li | 1 | 1 |
| Angela Fang Chen | 1 | 1 |
| Dai Jinming | 1 | 1 |
| Dai Jimming | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.